Sionna Therapeutics (NASDAQ:SION) Director Bruce Booth Sells 12,388 Shares

Key Points

• Director Bruce Booth of Sionna Therapeutics sold a total of 12,388 shares at an average price of $30.06, resulting in a transaction worth approximately $372,383.
• Sionna Therapeutics' stock is currently down by 3.2%, trading at $28.47, with a recent fifty-two week high of $30.60.
• Analysts have mixed ratings for Sionna Therapeutics, with a strong buy rating from Raymond James and a sector perform rating from Royal Bank of Canada, showing the stock's price targets range from $22.00 to $46.00.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Bruce Booth sold 12,388 shares of the company's stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $30.06, for a total transaction of $372,383.28. Following the completion of the transaction, the director owned 794,110 shares in the company, valued at approximately $23,870,946.60. This represents a 1.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Bruce Booth also recently made the following trade(s):

• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total transaction of $1,989,099.45.

Sionna Therapeutics Stock Down 3.2%

Sionna Therapeutics stock traded down $0.94 during trading hours on Wednesday, hitting $28.47. The company had a trading volume of 204,489 shares, compared to its average volume of 207,684. The firm's fifty day moving average is $22.47 and its 200-day moving average is $17.01. Sionna Therapeutics, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $30.60.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Wall Street Analyst Weigh In

SION has been the topic of several analyst reports. Raymond James Financial initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, September 2nd. They set a "strong-buy" rating and a $45.00 price target on the stock. Royal Bank Of Canada initiated coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price target on the stock. Jones Trading initiated coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They set a "buy" rating and a $46.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Sionna Therapeutics has an average rating of "Buy" and an average price target of $38.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in Sionna Therapeutics in the 1st quarter worth $109,258,000. TPG GP A LLC acquired a new stake in Sionna Therapeutics in the 1st quarter worth $69,925,000. Atlas Venture Life Science Advisors LLC acquired a new stake in Sionna Therapeutics in the 1st quarter worth $38,639,000. Braidwell LP acquired a new stake in Sionna Therapeutics in the 2nd quarter worth $18,770,000. Finally, Jennison Associates LLC acquired a new stake in Sionna Therapeutics in the 1st quarter worth $8,995,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.